PPARG and pulmonary arterial hypertension: In addition, administration of the PPAR-γ agonist rosiglitazone attenuates pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling in chronic hypoxia-exposed rats [12].